BR0315566A - Tetralinas e indanos substituìdos - Google Patents

Tetralinas e indanos substituìdos

Info

Publication number
BR0315566A
BR0315566A BR0315566-8A BR0315566A BR0315566A BR 0315566 A BR0315566 A BR 0315566A BR 0315566 A BR0315566 A BR 0315566A BR 0315566 A BR0315566 A BR 0315566A
Authority
BR
Brazil
Prior art keywords
indans
substituted tetralines
tetralines
substituted
tetralins
Prior art date
Application number
BR0315566-8A
Other languages
English (en)
Inventor
Xiaoli Chen
Keith T Demarest
Jung Lee
Jay M Matthews
Philip Rybczynski
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR0315566A publication Critical patent/BR0315566A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/08—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"TETRALINAS E INDANOS SUBSTITUìDOS". A presente invenção refere-se a compostos de tetralina e indano, composições contendo-os e métodos de uso dos mesmos como moduladores de PPAR alfa para tratar ou inibir a progressão de, por exemplo, diabetes.
BR0315566-8A 2002-10-21 2003-10-17 Tetralinas e indanos substituìdos BR0315566A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41992702P 2002-10-21 2002-10-21
US49575803P 2003-08-15 2003-08-15
PCT/US2003/033088 WO2004037777A1 (en) 2002-10-21 2003-10-17 Treating syndrome x with substituted tetralins and indanes

Publications (1)

Publication Number Publication Date
BR0315566A true BR0315566A (pt) 2005-08-23

Family

ID=32179770

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315566-8A BR0315566A (pt) 2002-10-21 2003-10-17 Tetralinas e indanos substituìdos

Country Status (17)

Country Link
US (2) US20040162352A1 (pt)
EP (1) EP1556344A1 (pt)
JP (1) JP2006503915A (pt)
KR (1) KR20050067419A (pt)
AU (1) AU2003279981A1 (pt)
BR (1) BR0315566A (pt)
CA (1) CA2503405A1 (pt)
CO (1) CO5690541A2 (pt)
EA (1) EA200500517A1 (pt)
HR (1) HRP20050337A2 (pt)
MX (1) MXPA05004296A (pt)
NO (1) NO20052277L (pt)
NZ (1) NZ539432A (pt)
PL (1) PL376470A1 (pt)
RS (1) RS20050319A (pt)
TW (1) TW200412935A (pt)
WO (1) WO2004037777A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0315596A (pt) * 2002-10-21 2005-09-06 Janssen Pharmaceutica Nv Tetralinas e indanos substituìdos
CN100354259C (zh) * 2002-10-21 2007-12-12 詹森药业有限公司 取代的四氢化萘和茚满及其用途
KR20060060047A (ko) 2003-10-01 2006-06-02 더 프록터 앤드 갬블 캄파니 멜라닌 농축 호르몬 길항제
AR048931A1 (es) * 2004-04-21 2006-06-14 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
US7550467B2 (en) * 2004-10-12 2009-06-23 Schering Corporation Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
US20060263450A1 (en) * 2005-05-17 2006-11-23 Julius Oben Method and composition for reducing body weight and improving control of body lipids
FR2896160B1 (fr) * 2006-01-13 2008-04-25 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agonistes du ppar alpha.
US20100098792A1 (en) * 2008-10-17 2010-04-22 Gateway Health Alliances, Inc. Methods and compositions using irvingia gabonensis to reduce weight, control obesity, effect adipogenesis, lower ppar-gamma, leptin, g3pdh and triglycerides levels and increase adiponectin levels
US20100098793A1 (en) * 2008-10-17 2010-04-22 Gateway Health Alliances, Inc. Irvingia gabonensis to treat and prevent metabolic syndrome and reduce total cholesterol, ldl cholesterol, blood glucose, c-reactive protein, and leptin levels and increasing adiponectin levels
US20130203769A1 (en) * 2012-02-08 2013-08-08 University Of Cincinnati Targeting Metabolic Adaptive Responses to Chemotherapy
WO2016092547A1 (en) 2014-12-09 2016-06-16 Ezekiel Golan Alcoholic beverage substitutes
CN112500301B (zh) * 2014-12-09 2024-02-13 以西结·戈兰 放纵行为调节剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU632809B2 (en) * 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
EP1259494A4 (en) * 2000-02-18 2004-09-15 Merck & Co Inc ARYLOXY ACETIC ACIDS FOR DIABETES AND LIPID DISEASES
NZ525119A (en) * 2000-10-05 2005-04-29 Bayer Ag Propionic acid derivatives
JPWO2002044129A1 (ja) * 2000-11-29 2004-04-02 杏林製薬株式会社 置換カルボン酸誘導体
JPWO2002046146A1 (ja) * 2000-12-05 2004-04-08 杏林製薬株式会社 置換カルボン酸誘導体
US7091225B2 (en) * 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists
US6548538B2 (en) * 2001-05-22 2003-04-15 Bayer Aktiengesellschaft Propionic acid derivatives
WO2003007887A2 (en) * 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
CN100354259C (zh) * 2002-10-21 2007-12-12 詹森药业有限公司 取代的四氢化萘和茚满及其用途
BR0315596A (pt) * 2002-10-21 2005-09-06 Janssen Pharmaceutica Nv Tetralinas e indanos substituìdos

Also Published As

Publication number Publication date
PL376470A1 (en) 2005-12-27
CA2503405A1 (en) 2004-05-06
AU2003279981A1 (en) 2004-05-13
CO5690541A2 (es) 2006-10-31
EA200500517A1 (ru) 2005-10-27
MXPA05004296A (es) 2005-11-23
RS20050319A (en) 2007-09-21
US20040162352A1 (en) 2004-08-19
JP2006503915A (ja) 2006-02-02
NO20052277L (no) 2005-06-29
TW200412935A (en) 2004-08-01
KR20050067419A (ko) 2005-07-01
EP1556344A1 (en) 2005-07-27
WO2004037777A1 (en) 2004-05-06
US20040171680A1 (en) 2004-09-02
NZ539432A (en) 2008-04-30
HRP20050337A2 (en) 2005-12-31
NO20052277D0 (no) 2005-05-10

Similar Documents

Publication Publication Date Title
BR0315566A (pt) Tetralinas e indanos substituìdos
CY1110326T1 (el) Υποκατασταθεισες τετραλινες και ινδανια και η χρηση τους
UY27884A1 (es) Moduladores del receptor de glucocorticoides
BR0308653A (pt) Cristais de derivado de benzeno de glicopiranosiloxibenzila
BRPI0417739A (pt) (s)-2-n-propilamino-5-hidroxitetralina como um agonista d3
BRPI0513709A (pt) processo para a fotoativação e uso de um catalisador por um procedimento de dois estágios invertido
UY26130A1 (es) Compuestos para tratar la obesidad
BR0113964A (pt) Composição adesiva à base de dispersões de policloropreno
BRPI0414634A (pt) agonistas de receptor b2, adrenérgico de etilamino amino-substituìdo
BR0305203A (pt) Preparação de poliissocianatos contendo grupos uretdiona
ECSP088316A (es) Moduladores sustituidos de 3-amido-tetrahidro-indazolil cannabinoide
BRPI0512395A (pt) composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou a profilaxia de condições ou distúrbios associadas(os) com a modulação de receptor de estrogênio seletiva, e para o tratamento ou a profilaxia relacionado(a) com condições ou distúrbios
BR0317229A (pt) Composição e uso de agonista completo de alfa7nachr
ATE370941T1 (de) Modulatoren des vitamin-d-rezeptors
CR20130055A (es) Compuestos aromáticos apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
AR047553A1 (es) La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
BR0315596A (pt) Tetralinas e indanos substituìdos
ATE295717T1 (de) Vitaminzusammensetzung für topische anwendungen
AR057362A1 (es) Procedimientos para preparar un inhibidor de mek
BRPI0519464A2 (pt) uso de certos compostos fenil-naftila que nço tÊm significante afinidade para er alfa ou beta para proteÇço de neurânios e oligodendràcitos no tratamento de esclerose méltipla
RS52507B (en) APPLICATION OF SPECIFIC HISTONS FOR THE TREATMENT OF PARASITIC DISEASES
BR0208157A (pt) Composições úteis para o tratamento de patologias respondendo à ativação de receptor ppar-gama
ECSP003458A (es) Compuestos para tratar la obesidad
HN2002000099A (es) Derivadposs de cromano 2,6 sustituidos utiles como agonistas adrenoreceptores beta - 3

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: JOHNSON AND JOHNSON (US)

Free format text: TRANSFERIDO DE: JANSSEN PHARMACEUTICA N.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.